SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular, oncology, and neurodegenerative diseases. SalubrisBio was founded in August 2016 as a wholly-owned subsidiary of the China-based pharmaceutical company Shenzhen Salubris Pharmaceuticals Co. Ltd.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/07/22 | $32,000,000 |
Salubris Pharmaceuticals | undisclosed | |
| 04/22/24 | $35,000,000 |
